Statistical and regulatory issues in nonrandomized medical device clinical studies

被引:13
|
作者
Lilly, Heng Li [1 ]
Yue, Lilly Q. [1 ]
机构
[1] US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
关键词
historical control; nonrandomized study; treatment group comparability;
D O I
10.1080/10543400701668233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
While randomized, well-controlled, clinical trials have been viewed as the gold standard in the evaluation of medical products, it is not uncommon for medical device clinical studies to depart from the paradigm of randomized trials, due to ethical or practical reasons. In nonrandomized studies, the advantages of well-designed and conducted randomized clinical trials are no longer available, and consequently the statistical inference obtained from such studies may carry a lower level of scientific assurance, compared to randomized trials. This paper provides a brief overview of nonrandomized medical device clinical studies in terms of design and statistical analysis as well as regulatory issues, including some challenges that frequently arise in those endeavors.
引用
下载
收藏
页码:20 / 30
页数:11
相关论文
共 50 条
  • [11] Adjustment of treatment effect for covariates in clinical trials: Statistical and regulatory issues
    Tu, DS
    Shalay, K
    Pater, J
    DRUG INFORMATION JOURNAL, 2000, 34 (02): : 511 - 523
  • [12] Statistical Issues in the Design and Analysis of Clinical Studies in Myeloma
    Crowley, John
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S39 - S39
  • [13] Adjustment of Treatment Effect for Covariates in Clinical Trials: Statistical and Regulatory Issues
    Dongsheng Tu
    Katherine Shalay
    Joseph Pater
    Drug information journal : DIJ / Drug Information Association, 2000, 34 (2): : 511 - 523
  • [14] A comparison of in vitro cytotoxicity assays in medical device regulatory studies
    Liu, Xuemei
    Rodeheaver, Denise P.
    White, Jeffrey C.
    Wright, Ann M.
    Walker, Lisa M.
    Zhang, Fan
    Shannon, Stephen
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2018, 97 : 24 - 32
  • [15] A Note on Good Practice of Objective Propensity Score Design for Premarket Nonrandomized Medical Device Studies with an Example
    Li, Heng
    Mukhi, Vandana
    Lu, Nelson
    Xu, Yun-Ling
    Yue, Lilly Q.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 282 - 286
  • [16] Regulatory Issues of Propensity Score Methodology Application to Drug and Device Safety Studies
    Levenson, Mark S.
    Yue, Lilly Q.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (01) : 110 - 121
  • [17] Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the United States
    Pesapane, Filippo
    Volonte, Caterina
    Codari, Marina
    Sardanelli, Francesco
    INSIGHTS INTO IMAGING, 2018, 9 (05): : 745 - 753
  • [18] Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the United States
    Filippo Pesapane
    Caterina Volonté
    Marina Codari
    Francesco Sardanelli
    Insights into Imaging, 2018, 9 : 745 - 753
  • [19] Longitudinal data analysis in medical device clinical studies
    Lao, Chang S.
    Bushar, Harry F.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (01) : 44 - 53
  • [20] Homogeneity assessment for pivotal medical device clinical studies
    Yan, Xu
    Ahn, Chul
    Chu, Jianxiong
    Dong, Li Ming
    Li, Heng
    Li, Xuefeng
    Lu, Hong
    Lu, Nelson
    Mukhi, Vandana
    Nair, Rajesh
    Tiwari, Ram
    Xu, Yunling
    Yue, Lilly Q.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 749 - 759